Johnson & Johnson $JNJ Stock Position Reduced by Aberdeen Group plc

Aberdeen Group plc decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,490,491 shares of the company’s stock after selling 238,558 shares during the quarter. Johnson & Johnson makes up approximately 0.7% of Aberdeen Group plc’s holdings, making the stock its 15th biggest holding. Aberdeen Group plc owned 0.10% of Johnson & Johnson worth $456,158,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. Abich Financial Wealth Management LLC acquired a new position in Johnson & Johnson in the 3rd quarter worth approximately $26,000. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson during the second quarter valued at $27,000. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson during the third quarter worth $28,000. Semmax Financial Advisors Inc. lifted its position in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. Finally, Compass Financial Services Inc boosted its stake in Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after acquiring an additional 198 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on JNJ. Royal Bank Of Canada lifted their price target on shares of Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Freedom Capital downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. Finally, Wolfe Research boosted their target price on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

Johnson & Johnson Price Performance

JNJ opened at $243.37 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.80 and a current ratio of 1.03. The stock has a market capitalization of $586.51 billion, a P/E ratio of 22.02, a P/E/G ratio of 2.36 and a beta of 0.35. The company’s 50-day simple moving average is $217.25 and its two-hundred day simple moving average is $196.59. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $246.35.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The business had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s payout ratio is presently 47.06%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New clinical data — 12‑month pilot results for the OMNY‑AF/OMNYPULSE atrial‑fibrillation platform showed strong success, supporting J&J’s device pipeline and longer‑term growth prospects. Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study
• Positive Sentiment: High‑profile endorsement — Jim Cramer publicly praised J&J, which can lift retail sentiment and trading interest in the near term. Johnson & Johnson (JNJ) is amazing, says Jim Cramer
• Positive Sentiment: Investor interest — coverage noting hedge‑fund ownership and favorable research commentary highlights institutional demand for JNJ as a defensive, cash‑generative mega‑cap. Why is Johnson & Johnson (JNJ) One of the Best Medical Research Stocks to Buy According to Hedge Funds?
• Neutral Sentiment: Analyst/valuation discussion — commentary (Forbes) examines whether JNJ remains attractive after a large multi‑quarter rally, noting strong fundamentals but higher expectations. This may temper upside but doesn’t change fundamentals. After A 55% Surge, Is JNJ Stock Still A Buy?
• Neutral Sentiment: Minor analyst action — Wall Street Zen cut JNJ to Hold, a modest signal that could pressure sentiment but not a major catalyst by itself. Johnson & Johnson (NYSE:JNJ) Cut to Hold at Wall Street Zen
• Negative Sentiment: Legal headline risk — A Pennsylvania jury found J&J liable in a talc/ovarian‑cancer case and awarded $250,000 to the plaintiff’s family. While the award is modest, the ruling renews media focus on J&J’s long‑running talc litigation and could sustain volatility or incremental settlement exposure. Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial Philadelphia Jury Returns $250,000 Verdict Against J&J

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.